News
Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over TA1054 15 April 2025 15 April 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback